Autologous t-cell activation fosters ABT-199 resistance in chronic lymphocytic leukemia: Rationale for a combined therapy with SYK inhibitors and anti-CD20 monoclonal antibodies by Elías, Esteban Enrique et al.
Autologous T-cell activation fosters ABT-199 
resistance in chronic lymphocytic leukemia: 
rationale for a combined therapy with SYK inhibitors
and anti-CD20 monoclonal antibodies
Leukemic B cells from chronic lymphocytic leukemia
(CLL) patients survive and proliferate within lymphoid
tissues in contact with activated T cells, myeloid cells and
by receiving signals through the B-cell receptor (BCR).
ABT-199 (venetoclax) is a potent, selective inhibitor of B-
cell lymphoma 2 (BCL-2) with promising clinical activity
in CLL patients. ABT-199 rapidly induces apoptosis in
unstimulated peripheral blood CLL cells in vitro, while
CLL cells that have received survival signals from the
microenvironment are less sensitive to the drug. In par-
ticular, signaling through the BCR or signals provided by
fibroblast CD40L+ and by stromal cell lines were shown
to reduce the sensitivity of CLL cells to ABT-199.1-3 In the
study herein, we investigated whether resistance to 
ABT-199 can be conferred by autologous T-cell activa-
tion, another important survival signal from the protec-
tive niches. We first confirmed that peripheral blood
leukemic cells from CLL patients are sensitive to ABT-
199 in vitro in a dose-dependent manner (Online
Supplementary Figure S1), while T cells (CD3+ CD56–), nat-
ural killer (NK) cells (CD3– CD56+), and monocytes
(CD14+) are less sensitive to the drug (Figure 1A).
Therefore, the cell death induced on CD19+ cells at 24
hours of culture with 0.01µM of ABT-199 is not possible
to reach, even with a hundred times more concentrated
dose of ABT-199 on accessory cells (Figure 1A). Next,
peripheral blood mononuclear cells (PBMC) from CLL
patients were cultured on immobilized anti-CD3 mono-
clonal antibodies (mAbs; aCD3) to induce autologous T-
cell activation. As expected, aCD3 upregulated expres-
sion of the activation markers CD69 and CD25 on CD4+
and CD8+ T cells at 24 hours (data not shown). This was
not affected, or was only slightly reduced, by the pres-
ence of clinically relevant doses of ABT-199 (Figure 1B),
suggesting that the drug does not significantly affect T-
cell activation. Subsequently, we compared the impact of
ABT-199 on the survival of unstimulated CLL cells or CLL
cells that had received signals from autologous activated
T cells. To this end PBMC from CLL patients were incu-
bated with or without aCD3 for 48 hours, then ABT-199
was added to cell culture. As depicted in Figure 1C,
leukemic cells cultured in the presence of activated T
lymphocytes were clearly less sensitive to the drug com-
pared to leukemic cells cultured with non-activated T
cells, showing that autologous T-cell activation induced
in vitro ABT-199 resistance in CLL cells, even at concen-
trations as high as 1µM.  Similar results were obtained
when purified leukemic cells were cultured with purified
CD3+ lymphocytes from the same patient (Online
Supplementary Figure S2A). In line with this, we found a
positive correlation between ABT-199 resistance induced
in aCD3 cultures and the percentage of CD3+ cells within
the PBMC of each patient (Online Supplementary Figure
S2B). Moreover, the inferior degree of resistance to ABT-
199 in Figure 1C (see open dots in Figure 1C) was
observed with samples from Patients N° 8, 15 and 17
who had very low percentages of T cells within their
PBMC (see Online Supplementary Table S1), while no
other clinical or biological association was found. Since
CLL patients generally have higher absolute numbers of
CD3+ cells,4 which are mainly localized within the prolif-
eration centers of lymphoid tissues where activated T
cells tend to cluster around proliferating CLL cells,5,6 our
results suggest that tissue-resident leukemic cells might
not be properly targeted by ABT-199. 
The activation of autologous T cells increased the
expression of the activation marker CD86 in CLL cells in
all of the patients evaluated (Figure 1D), and, more inter-
estingly, it induced the upregulation of the antiapoptotic
proteins MCL-1 and BCL-XL on CLL cells (Figure 1E).
The fact that these proteins from the BCL-2 family are
not targeted by ABT-199 may explain the resistance
induced by activated T cells, which has also been sug-
gested by recent studies analyzing other microenviron-
ment signals.1-3 In an attempt to restore ABT-199 sensitiv-
ity in CLL cells, we employed the BCR kinase inhibitor
(BCR-KI) GS-9973 (entospletinib), which inhibits SYK
and is an attractive novel therapeutic agent for CLL.7 As
shown in Figure 1F, we found that a clinically relevant
concentration of GS-9973 (1µM) was able to reduce the
resistance to ABT-199 induced by activated T cells. 
We recently reported that GS-9973 thwarts T-cell acti-
vation in CLL patients, not only impairing the expression
of CD25 and CD69 on CD3-stimulated T cells, but also
reducing the proliferation and the cytokine production by
T cells.8 Moreover, when the direct effect of GS-9973 on
the survival of CD19+ cells from CLL patients cells was
evaluated, we found that it only slightly reduced
leukemic cell survival, but not in a statistically significant
way, and did not particularly sensitize malignant cells to
ABT-199 induced cell death (Online Supplementary Figure
S3). Altogether, our observations suggest that the effect
of GS-9973 on T-cell activation could most likely be
involved in the capacity of GS-9973 to overcome the
ABT-199 resistance observed in aCD3 cultures.
Our findings strengthen the role of the tumor microen-
vironment in the promotion of drug resistance, which
might account for the progression of the disease in ABT-
199 monotherapy-treated CLL patients.10 They also
encourage the combination of ABT-199 with BCR-KIs,
which impair activation signals provided by the tumor
microenvironment.10 In the case of GS-9973, while we
found that it overcomes the resistance to ABT-199
induced by activated T cells (Figure 1F), the reports of
others showed that it prevents BCR-mediated resistance
of CLL cells to the drug more efficiently than other BCR-
KIs.2
Given that the triple combination of ABT-199 with
BCR-KIs and anti-CD20 mAbs appears to be an attractive
strategy (see www.clinicaltrials.gov Identifiers: 03379051,
02950051, 02758665, 02296918 and 02427451), we
aimed to determine whether ABT-199 may affect phago-
cytosis of rituximab-coated CLL cells, which is a central
mechanism in the anti-tumor activity of anti-CD20 anti-
bodies.11,12 Macrophages were exposed to different doses
of ABT-199, then carboxyfluorescein succinimidyl ester
(CFSE)-labeled CLL cells or rituximab-coated CFSE-
labeled CLL were added to the culture. Phagocytosis was
evaluated after 1 hour. Preincubation of macrophages
with ABT-199 for 3 hours (Online Supplementary Figure
S4) or 18 hours (data not shown) did not modify their
capacity to uptake uncoated or rituximab-coated CLL
cells. On the other hand, preincubation of purified CLL
cells with ABT-199 significantly increased their uptake by
macrophages, not only when coated with rituximab but
also in its absence (Figure 2A,B). This interesting finding
could be due to the exposure of “eat-me signals” on dying
CLL cells which prompts macrophages to engulf them.13
Given that phosphatidylserine (PtdSer) exposure during
apoptosis is one of the best characterized “eat-me sig-
nals”,13 we evaluated Annexin V binding to PtdSer on
purified CLL cells incubated, or not, with ABT-199 for 3
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Figure 1. The activation of autologous T lymphocytes induces ABT-199 resistance in CLL which is overcome by GS-9973. A) PBMC from CLL patients (n= 30,
4 x 106 cells/mL) were cultured with DMSO (vehicle) or different doses of ABT-199. The survival of CD19+, CD3+CD56–, CD3–CD56+and CD14+ cells were evalu-
ated daily by flow cytometric alterations of light-scattering properties (Online Supplementary Figure S1A) and confirmed by Annexin V-FITC assay (Online
Supplementary Figure S1B). The figure shows the mean ± SEM of the percentage of cells within the gate of viable cells at 24 hours in control and ABT-199 cul-
tures. Statistical analysis was performed using the Friedman test followed by Dunn’s multiple comparison test. *P<0.05, ****P<0.0001, treated vs. control.
B) PBMC from CLL patients (n=15, 4x106 cells/mL) were cultured with aCD3 (50 ng/well, 48-well plate) or the corresponding isotype control (data not shown)
for 24 hours with or without ABT-199. Then, the expression of CD69 and CD25 on CD4+ and CD8+ T cells were evaluated by flow cytometry. The figure shows
the mean ± SEM of the percentage of CD4+ or CD8+ cells expressing CD25 or CD69 in each condition. Statistical analysis was performed using the Friedman
test followed by Dunn’s multiple comparison test,*P<0.05, treated vs. control. C) PBMC from CLL patients (4 x 106 cells/mL) were cultured with aCD3 (50
ng/well, 48-well plate) or the corresponding isotype control for 48 hours. Then, ABT-199 or DMSO were added to the cultures for another 24 hours. The survival
of CD19+ cells was evaluated as mentioned above. The graph shows the mean ± SEM of the percentage of CD19+ cells within the gate of viable cells and the
results obtained with each CLL patient (n=18) are also shown. Open circles highlight CLL patients with less than 1% of T cells within PBMC (Patients #8, #15
and #17 of Online Supplementary Table S1). Statistical analysis was performed using the Friedman test followed by Dunn’s multiple comparison test,
**P<0.01. D) PBMC from CLL patients (n=19, 4x106 cells/mL) were cultured with aCD3 or the isotype control (control cultures) for 48 hours. The expression
of the activation marker CD86 on CLL cells (CD19+) was evaluated by flow cytometry. The figure shows the percentage of CD19+CD86+ cells of each patient in
control and aCD3 cultures. Statistical analysis was performed using the Wilcoxon matched pair test, ****P<0.0001. E) PBMC from CLL patients (n=8, 4x106
cells/mL) were cultured with or without aCD3 for 48 hours. Next, BCL-XL and MCL-1 expression on purified CLL cells were evaluated by Western Blot as detailed
in the Online Supplementary Materials and Methods. The figure shows the expression of BCL-XL, MCL-1 and ACTIN in control and aCD3 cultures. F) PBMC from
CLL patients (4x106  cells/mL) were cultured with or without aCD3, in the presence or absence of GS-9973 (1 µM) for 48 hours. Then, ABT-199 was added to
the cultures for another 24 hours. CD19+ cell survival was evaluated as mentioned above. The figure shows the mean ± SEM of the percentage of CD19+ cells
within the gate of viable cells, and the results obtained with each CLL patient (n=18) are also shown. Statistical analysis was performed, using the Friedman
test followed by Dunn’s multiple comparison test, **P<0.01. CLL: chronic lymphocytic leukemia.
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Figure 2. ABT-199 enhances CLL cells phagocytosis by macrophages. A-B) Purified CFSE-labeled CLL cells (n=20) were cultured for 3 hours with ABT-199 or
DMSO and then coated or not with rituximab (50 µg/mL). The phagocytosis assay was performed as detailed in the Online Supplementary Materials and
Methods with macrophages obtained by culturing monocytes from healthy donors PBMC in complete medium with MCSF (50 ng/mL) for 5 days. The phagocy-
tosis was evaluated by flow cytometry after 1 hour of culture when macrophages were trypsinized. The bars in Figure A show the percentage of macrophages
(determined by morphology in the FSC-H and SSC-H dot plot) that have taken up CFSE-labeled CLL cells. Statistical analysis was performed using the Friedman
test followed by Dunn’s multiple comparison test.*P<0.05, **P<0.01, ****P<0.0001. Representative dot plots showing FSC-H and CFSE with the percentage
of macrophages in each quadrant are shown in Figure B. C-D) PBMC from CLL patients were cultured with ABT-199 or DMSO for 3 hours. PtdSer exposure
induced by ABT-199 was evaluated by Annexin-V binding using Annexin-V FITC and PI. Figure C shows the mean ± SEM of the percentage of Annexin V+ PI- cells
in each condition, and the results obtained with each patient (n=9) is also shown. Statistical analysis was performed using the Friedman test followed by Dunn’s
multiple comparison test, ***P<0.001. Representative dot plots showing the Annexin V-FITC binding and PI staining of control and ABT-199 cultures, while the
percentages of cells in each quadrant are shown in Figure D. E-F) PBMC from CLL patients treated or not with ABT-199 (1 µM) for 3 hours were then coated, or
not, with rituximab and the antibody binding was evaluated by flow cytometry using anti-human IgG FITC. Figure E shows the mean ± SEM of the mean fluores-
cence intensity (MFI) of anti-human IgG FITC in control and ABT-199 cultures. The results obtained from each patient (n=9) is also shown. Statistical analysis
was performed using the Friedman test followed by Dunn’s multiple comparison test. Representative histogram showing rituximab binding on CLL cells treated
or not with ABT-199 for 3 hours are depicted in Figure F. G) Purified CFSE-labeled CLL cells were cultured for 3hours with ABT-199 or DMSO and then coated,
or not, with rituximab. The phagocytosis assay was performed as mentioned above, with macrophages pre-incubated 30 min with or without GS-9973 (n=13).
Statistical analysis was performed using the Friedman test followed by Dunn’s multiple comparison test, *P<0.05. CLL: chronic lymphocytic leukemia; DMSO:
dimethyl sulfoxide.
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hours. Results from Figure 2C confirm increased Annexin
V binding in ABT-199-treated CLL cells. Representative
dot plots are shown in Figure 2D. By contrast, rituximab
binding to CLL cells was unaffected or even seemingly
reduced by the drug (Figure 2E). Representative his-
tograms of rituximab binding are shown in Figure 2F. The
enhanced phagocytosis of rituximab-coated ABT-199-
treated CLL cells might account for the substantial bene-
fit showed in CLL patients treated with ABT-199 and rit-
uximab compared with ABT-199 monotherapy.14
Finally, to test whether the stimulatory effect of ABT-
199 on phagocytosis also functions in the presence of GS-
9973, CLL cells were preincubated with or without ABT-
199, as mentioned above, and phagocytosis was per-
formed with macrophages treated, or not treated, with
GS-9973.8 We found that GS-9973 does not modify the
uptake of uncoated CLL cells by macrophages (Figure
2G). Moreover, we confirmed our previous data, showing
that GS-9973 reduced phagocytosis of rituximab-coated
CLL cells,8 and found that it also impairs the phagocytosis
of ABT-199-treated CLL cells coated with rituximab.
However, ABT-199 fostered uptake of rituximab-coated
CLL cells in the presence of GS-9973 (Figure 2G).
In conclusion, the resistance observed in vitro when
CLL cells were cultured with autologous activated T cells
suggests that leukemic cells from the supportive microen-
vironment might not be properly targeted by ABT-199
monotherapy. Our results encourage the combination of
the drug with a BCR-KI, such as GS-9973, which over-
came the resistance induced by activated T cells and
other microenvironment signals.2 The combination with
anti-CD20 mAbs could also be useful as ABT-199
enhanced phagocytosis of rituximab-coated CLL cells,
even in the presence of GS-9973.
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